CLAIMS

1. A pharmaceutical composition comprising a dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor for use as a medicament wherein a total daily dosage of the dopamine replacement agent is administrated by:
    a. Administrating a first dosage of the pharmaceutical composition wherein the first dosage is 20-35% of the total daily dosage of the dopamine replacement agent; and
    b. Continuously administrating a second dosage of the pharmaceutical composition wherein the second dosage adds up to the total daily dosage of the dopamine replacement agent.
2. The pharmaceutical composition of claim 1 wherein the method comprises:
    a. Administrating a first dosage of the pharmaceutical composition wherein the first dosage is 20-35% of the total daily dosage of the dopamine replacement agent;
    b. Continuously administrating a second dosage of the pharmaceutical composition wherein the second dosage adds up to the total daily dosage of the dopamine replacement agent; wherein a first portion of the second dosage is first continuously administrated for a predetermined time where after a second portion of the second dosage is continuously administrated, wherein the sum of the first and second portion adds up to the second dosage and wherein, for the second portion, a lower amount of the dopamine replacement agent is administrated per time unit.
3. The pharmaceutical composition of claim 1 or 2, wherein the dopamine replacement agent is levodopa or a pharmaceutically acceptable salt or derivative thereof.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the dopamine decarboxylase inhibitor is selected from the group consisting of carbidopa, benserazide and combinations thereof.
5. The pharmaceutical composition according to claim 4, wherein the dopamine decarboxylase inhibitor is carbidopa.

6. The pharmaceutical composition according to any one of claims 1-5, wherein the COMT inhibitor is selected from the group consisting of entacapone, tolcapone, opicapone, and combinations thereof.
7. The pharmaceutical composition according to claim 5, wherein the COMT inhibitor is entacapone.
8. The pharmaceutical composition according to any one of claims 1-7, wherein the composition further comprises a substance inhibiting degradation of carbidopa to hydrazine.
9. The pharmaceutical composition according to claim 8, wherein the substance comprises entacapone.
10. The pharmaceutical composition according to any one of the preceding claims wherein the dopamine replacement agent, the dopamine decarboxylase inhibitor (DDI), and the catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants is contained in a single pharmaceutical composition.
11. The pharmaceutical composition according to any one of claims 1 to 10 wherein the pharmaceutical composition comprises a first, second and a third part wherein the first part comprises the dopamine replacement agent, the second part comprises the dopamine decarboxylase inhibitor (DDI), and the third part comprises the catechol-O-methyltransferase (COMT) inhibitor, and wherein each part may optionally contain suitable adjuvants, or wherein the pharmaceutical composition comprises a first part comprising the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI) and a second part comprising the COMT inhibitor and wherein each part optionally contains suitable adjuvants.
12. The pharmaceutical composition according to any one of claims 1 to 10 wherein the dopamine replacement agent, the dopamine decarboxylase inhibitor (DDI), and the catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants of the first dosage are administrated individually, or wherein the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI) are administrated at the same time and wherein the COMT inhibitor is administrated essentially at the same time as the dopamine replacement agent and the dopamine decarboxylase inhibitor (DDI).

13. The pharmaceutical composition according to any of the preceding claims wherein the total daily dosage of dopamine replacement agent is 200 to 3500 mg such as 400-3000mg.
14. The pharmaceutical composition according to any of the preceding claims wherein the patient suffers from Parkinson's disease.
15. The pharmaceutical composition according to claim 14 wherein the patient suffers from hyperkinetic sensitivity or has a tendency to become hyperkinetic.
16. The pharmaceutical composition according to any one of claims 1 to 14 wherein the continuous administration is performed continuously for 24 hours.
17. The pharmaceutical composition according to claim any one of claims 1 to 15 wherein the continuous administration is performed continuously for 12-18 hours, such as 13-17 hours or 14-16 hours.
18. The pharmaceutical composition according to any one of the preceding claims wherein the first dosage is administrated in the morning such as between 5am and 10am.
19. The pharmaceutical composition according to any one of the preceding claims wherein the composition of the first dosage is an oral composition, a liquid composition, a suspension or a gel.
20. The pharmaceutical composition according to claim 19 wherein the first dosage is administrated orally, intravenously, subcutaneously, intra-intestinally or dermally.
21. The pharmaceutical composition according to any one of the preceding claims wherein the composition of the second dosage is a liquid composition, a suspension or a gel.
22. The pharmaceutical composition according to claim 21 wherein the second dosage is administrated intravenously, subcutaneously, intra-intestinally or dermally.
23. A kit comprising a first container and at least one additional container wherein the first and the at least one additional container comprises a first and a second dosage respectively of a pharmaceutical composition according to any one of claims 1 to 22 for use as a medicament, wherein:
    a. the first dosage comprises 20-35% of the total daily dosage of the dopamine replacement agent; and
    b. the second dosage adds up to the total daily dosage of the dopamine replacement agent;

and wherein at least the second dosage is a liquid pharmaceutical composition, a suspension or a gel.

24. The kit according to claim 23, wherein both the first and second dosages are in the form of a liquid pharmaceutical composition, a suspension or a gel.

25. A method of administrating a total daily dosage of a dopamine replacement agent to a patient in need thereof by a pharmaceutical composition comprising the dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor, and optionally suitable adjuvants; wherein the method comprises:

a. Administrating a first dosage of the pharmaceutical composition wherein the first dosage comprises 20-35% of the total daily dosage of the dopamine replacement agent; and

b. Continuously administrating a second dosage of the pharmaceutical composition wherein the second dosage adds up to the total daily dosage of the dopamine replacement agent.

26. The method according to claim 25 wherein the method comprises

a. Administrating a first dosage of the pharmaceutical composition wherein the first dosage is 20-35% of the total daily dosage of the dopamine replacement agent;

b. Continuously administrating a second dosage of the pharmaceutical composition wherein the second dosage adds up to the total daily dosage of the dopamine replacement agent; wherein a first portion of the second dosage is first continuously administrated for a predetermined time where after a second portion of the second dosage is continuously administrated, wherein the sum of the first and second portion adds up to the second dosage and wherein, for the second portion, a lower amount of the dopamine replacement agent is administrated per time unit.